Off-label use of rituximab for systemic lupus erythematosus in Europe.

Monica Rydén-AulinDimitrios BoumpasIrene BultinkJose Luis Callejas RubioLuis Caminal-MonteroAntoni CastroAgustín Colodro RuizAndrea DoriaThomas DörnerCristina Gonzalez-EchavarriElisa GremeseFrederic A HoussiauTom HuizingaMurat InançDavid IsenbergAnnamaria IulianoSøren JacobsenJuan Jimenéz-AlonsoLászlo KovácsXavier MarietteMarta MoscaOla NivedJoaquim OristrellManuel Ramos-CasalsJavier RascónGuillermo Ruiz-IrastorzaLuis Sáez-CometGonzalo Salvador CervellóGian Domenico SebastianiDanilo SquatritoGabriella SzücsAlexandre VoskuylRonald van Vollenhoven

Published in: Lupus science & medicine (2016)

RTX use for SLE in Europe is restrictive and appears to be used as a last resort in patients for whom other reasonable options have been exhausted.

Keyphrases

systemic lupus erythematosus
end stage renal disease
disease activity
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
diffuse large b cell lymphoma
prognostic factors
patient reported outcomes